Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (REALiTEC/TAL)

Last Updated   May 16, 2025

Want to learn how to participate in this trial?

64007957MMY4004

OVERVIEW

  • Sexes Eligible for Study
    all
  • Age
    18+ years
  • Phase
  • Sites
    37 Sites
  • Status
    Recruiting

SUMMARY

The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

CONDITIONS

  • Relapsed/Refractory Multiple Myeloma (RRMM)

ELIGIBILITY


Inclusion Criteria:

* Have a documented diagnosis of multiple myeloma
* Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab & talquetamab can be included in both REALiTEC and REALiTAL cohorts
* Received at least one dose of teclistamab/talquetamab
* Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements


Exclusion Criteria:

* To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial
* To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial
* Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2


Inclusion Criteria:

* Have a documented diagnosis of multiple myeloma
* Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to

More...

DETAILS

LOCATIONS

Locations in:
France, Germany, Israel, Spain, Sweden, Denmark, Ireland, Italy, United Kingdom
Country (9) City or Province (37) Status
France Lille cedex Hopital Albert Calmette - CHU Lille
RECRUITING
France Marseille Institut Paoli Calmettes
RECRUITING
France Paris Hopital Saint Louis
RECRUITING
France Toulouse Cedex 9 Institut Universitaire du Cancer Toulouse Oncopole
RECRUITING
France Vandœuvre-lès-Nancy CHRU de Nancy - Hopitaux de Brabois
RECRUITING
Germany Heidelberg Uniklinikum Heidelberg
RECRUITING
Germany Wurzburg Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii
RECRUITING
Israel Ramat Gan Sheba Medical Center
RECRUITING
Israel Tel Aviv Yafo Tel Aviv Sourasky Medical Center
RECRUITING
Spain Madrid Hosp. Univ. de La Paz
RECRUITING
Sweden Goteborg Sahlgrenska University Hospital
RECRUITING
Sweden Jonkoping Länssjukhuset Ryhov
RECRUITING
Sweden Stockholms Karolinska Universitetssjukhuset
RECRUITING
Denmark Copenhagen Rigshospitalet
COMPLETED
Denmark Vejle Sygehus Lillebælt, Vejle
COMPLETED
Germany Chemnitz Klinikum Chemnitz gGmbH
RECRUITING
Germany Dresden Universitatsklinikum Carl Gustav Carus Dresden
RECRUITING
Germany Hamburg University Hospital Hamburg Eppendorf
RECRUITING
Ireland Cork N/a Cork University Hospital
COMPLETED
Ireland Dublin St James Hospital
COMPLETED
Ireland Galway University Hospital Galway - Ireland
RECRUITING
Israel Jerusalem Hadassah Medical Center
RECRUITING
Italy Bologna Policlinico Sant'Orsola Malpighi
COMPLETED
Italy Firenze AOU Careggi
COMPLETED
Italy Milano Policlinico di Milano
COMPLETED
Italy Napoli Azienda Ospedaliera Universitaria Federico II
RECRUITING
Italy Palermo Casa di Cura La Maddalena
RECRUITING
Italy Roma Universita Cattolica del Sacro Cuore - Fondazione Policlinico Universitario 'A. Gemelli'
RECRUITING
Spain Malaga Hosp. Costa Del Sol
COMPLETED
Sweden Uddevalla Uddevalla Hospital
RECRUITING
United Kingdom Birmingham Queen Elizabeth Hospital
COMPLETED
United Kingdom London University College Hospital
COMPLETED
Denmark Odense Odense University Hospital
RECRUITING
France Nantes CHU de Nantes hotel Dieu
RECRUITING
Germany Nuernberg Klinikum Nurnberg Nord
COMPLETED
Italy Roma Presidio Ospedaliero Santo Spirito in Sassia
RECRUITING
United Kingdom London Guys and St Thomas NHS Foundation Trust
COMPLETED
Show More
Geo Locations

50.63297, 3.05858

43.29551, 5.38958

48.85341, 2.3488

43.60426, 1.44367

48.65, 6.18333

49.40768, 8.69079

49.79391, 9.95121

32.08227, 34.81065

32.08088, 34.78057

40.4165, -3.70256

57.70716, 11.96679

57.78145, 14.15618

59.2796333, 17.9742656

55.67594, 12.56553

55.70927, 9.5357

50.8357, 12.92922

51.05089, 13.73832

53.57532, 10.01534

53.7797554, -7.3055309

53.33306, -6.24889

53.27194, -9.04889

31.76904, 35.21633

44.49381, 11.33875

43.77925, 11.24626

45.46427, 9.18951

40.85216, 14.26811

38.13205, 13.33561

41.89193, 12.51133

36.72016, -4.42034

58.34784, 11.9424

52.48142, -1.89983

51.50853, -0.12574

55.39594, 10.38831

47.21725, -1.55336

49.45421, 11.07752

41.89193, 12.51133

51.50853, -0.12574

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.